Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.

Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.

Item
http://www.wikidata.org/entity/Q55463474
A neuroradiologist's guide to arterial spin labeling MRI in clinical practiceCombination therapy for renal cell cancer: what are possible options?Early-stage imaging of nanocarrier-enhanced chemotherapy response in living subjects by scalable photoacoustic microscopy.Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors.Sorafenib in advanced melanoma: a critical role for pharmacokinetics?Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation.Clinical oncologic applications of PET/MRI: a new horizon.Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma.Treatment selection in metastatic renal cell carcinoma: expert consensus.Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.Antiangiogenic Effect of Bevacizumab: Application of Arterial Spin-Labeling Perfusion MR Imaging in a Rat Glioblastoma Model.Pseudo-continuous arterial spin labeling reflects vascular density and differentiates angiomatous meningiomas from non-angiomatous meningiomas.Computational Fractal-Based Analysis of MR Susceptibility-Weighted Imaging (SWI) in Neuro-oncology and Neurotraumatology
P2860

Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.

Item
http://www.wikidata.org/entity/Q55463474
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Early evaluation of tumoral re ...... lastoma receiving bevacizumab.
@en
Early evaluation of tumoral re ...... lastoma receiving bevacizumab.
@nl
type
label
Early evaluation of tumoral re ...... lastoma receiving bevacizumab.
@en
Early evaluation of tumoral re ...... lastoma receiving bevacizumab.
@nl
prefLabel
Early evaluation of tumoral re ...... lastoma receiving bevacizumab.
@en
Early evaluation of tumoral re ...... lastoma receiving bevacizumab.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Early evaluation of tumoral re ...... lastoma receiving bevacizumab.
@en
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921